Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT03778619
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National Univ. Hospital, Seoul, Korea, Republic of
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
- Conditions
- Interventions
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 129
- Registration Number
- NCT03666000
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
- Conditions
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 18
- Registration Number
- NCT03546426
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy
High Dose IL 2 and Entinostat in RCC
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Roberto Pili
- Target Recruit Count
- 46
- Registration Number
- NCT03501381
- Locations
- 🇺🇸
Univeristy of Southern California, Los Angeles, California, United States
🇺🇸Hematology Oncology Clinic, LLC, Baton Rouge, Louisiana, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Ralph Hauke
- Target Recruit Count
- 1
- Registration Number
- NCT03476174
- Locations
- 🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
- Conditions
- Interventions
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 18
- Registration Number
- NCT03475134
- Locations
- 🇨🇭
CHUV Oncology Department, Lausanne, Vaud, Switzerland
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Megan Daly, MD
- Target Recruit Count
- 45
- Registration Number
- NCT03474497
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT03412526
- Locations
- 🇮🇱
Sheba medical Center, Ramat Gan, Israel
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 7
- Registration Number
- NCT03287674
- Locations
- 🇩🇰
Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Denmark
Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT03241719
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.